Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)

  1. Drake, M.J.
  2. Chapple, C.
  3. Esen, A.A.
  4. Athanasiou, S.
  5. Cambronero, J.
  6. Mitcheson, D.
  7. Herschorn, S.
  8. Saleem, T.
  9. Huang, M.
  10. Siddiqui, E.
  11. Stölzel, M.
  12. Herholdt, C.
  13. MacDiarmid, S.
Revue:
European Urology

ISSN: 1873-7560,  0302-2838

Année de publication: 2016

Volumen: 70

Número: 1

Pages: 136-145

Type: Article

DOI: 10.1016/J.EURURO.2016.02.030 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus